Compare NPWR & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPWR | BDSX |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Precision Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.0M | 153.3M |
| IPO Year | 2021 | 2020 |
| Metric | NPWR | BDSX |
|---|---|---|
| Price | $1.92 | $55.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.50 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 909.8K | 101.4K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.35 | $0.35 |
| 52 Week High | $5.20 | $27.11 |
| Indicator | NPWR | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 59.56 |
| Support Level | $1.63 | $19.26 |
| Resistance Level | $2.15 | N/A |
| Average True Range (ATR) | 0.16 | 2.30 |
| MACD | 0.04 | 0.13 |
| Stochastic Oscillator | 72.73 | 80.44 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. Its business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. The company has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.